The August issue is out now! Highlights include a feature on the current state of #GeneTherapy in #hematology, meeting coverage of #ISTH25, a debate on combination therapy for #myelofibrosis, and more. Check out the full lineup here: 🩸

Long-term research presented at #ISTH25 affirmed that CHIP has an independent negative effect on overall survival, but treatments for #CoronaryArteryDisease in patients who were CHIP-positive did not help overcome this effect:

RT @doctorpemm: 👉👉👉Delighted to share our brand new MPN debate & article in @ASHClinicalNews @ASH_hematology | . @GabyHobbs & @doctorpemm….

RT @WileyOnc_Hem: The Aug issue of @ASHClinicalNews is here!. This month's issue explores complex topics such as how to approach HLA typing….

#ISTH25 Use of the EULAR 2023 criteria — developed to refine the classification of #AntiphospholipidSyndrome — was found to improve specificity compared with the 2006 Sydney criteria but resulted in decreased sensitivity, leaving many patients excluded:

Recent research indicates that MRD-guided time-limited treatment with #zanubrutinib, #venetoclax, and #obinutuzumab resulted in deep remissions in patients with previously treated #ChronicLymphocyticLeukemia, with a best uMRD rate of 85%:

Interested in joining the team? ASH Clinical News is seeking associate editors! Editors have the chance to share their views on topics in the field, participate in content development, and more. For more information and to apply by August 15, visit: 🩸.

#MentalHealth may play a significant role in #lymphoma and #MultipleMyeloma #MMsm. According to a recent study, 52% and 27.5% of adults met the diagnostic criteria for #anxiety and #depression, respectively, in the first six months after a diagnosis of lymphoma or MM.

At seven years of follow-up, #daratumumab showed continued single-agent clinical activity in patients with intermediate or high-risk #SmolderingMultipleMyeloma with no new safety concerns, according to the final analysis of the phase II CENTAURUS study:

Check out what's new in the July issue! Highlights include a feature on the Trump administration's impact on #hematology in its first 100 days, testing and treatment of elevated factor levels post-stroke, recent findings from #ASCO25 and #EHA25, and more:

RT @JhaveriKhushali: 🚨Just published in @ASHClinicalNews:. What does moral injury look like in oncology? Not about being tired — but about….

The #FDA recently approved tafasitamab in combination with #rituximab and #lenalidomide to treat #FollicularLymphoma in adults, based on findings showing a 22.4-month median PFS with the therapy compared with 13.9 months in the control arm:

RT @WileyOnc_Hem: Research published in @haemophilia_jnl reveals that providers may be insufficiently screening — and thus undertreating —….

Using #ctDNA, genetic subtypes of classical #Hodgkin #lymphoma were found to be driven by the mechanism of genetic instability rather than the grouping of #mutations into functional categories, according to new findings published in @BloodPortfolio:

RT @WileyOnc_Hem: Editor-in-Chief @AaronGerds, MD, shares highlights from the July issue of @ASHClinicalNews, including a feature on the Tr….

When used in combination with other medications, #venetoclax appears to be effective in patients with R/R #MultipleMyeloma #MMsm harboring t(11;14), with an ORR of 64%, but is less efficacious when certain other chromosomal abnormalities are also present:

ASH Clinical News is seeking associate editors! Editors have the opportunity to share their views on topics in #hematology, participate in content development, and provide subject matter expertise. For more information and to apply by August 15, visit:

According to findings from #EHA2025, patients with newly diagnosed #MultipleMyeloma #MMsm that was treated with Isa-KRd saw increased levels of sustained MRD negativity compared with patients treated with a combination that did not include #isatuximab:

According to data from #EHA2025, GLPG5101, a fresh, stem-like, early memory phenotype CD19-directed #CARTcell therapy, demonstrated a manageable safety profile in patients with R/R #nonHodgkin #lymphoma, producing low rates of high-grade toxicities:

When compared with the standard assays to assess #ADAMTS13 activity for suspected TTP, newer point-of-care rapid assays demonstrated higher diagnostic accuracy and concordance and lower rates of discrepancies: #thrombosis #ClottingDisorders #classicalheme.